Animal health company Elanco (NYSE: ELAN) reported Q1 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $1.19 billion. The company’s full-year revenue guidance of $4.55 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.37 per share was 21.5% above analysts’ consensus estimates.

Is now the time to buy ELAN? Find out in our full research report (it’s free).

StockStory’s Take

Elanco’s first quarter results reflected steady progress in product innovation and portfolio diversification, with management emphasizing the contribution of its recently launched products. CEO Jeff Simmons highlighted that organic constant currency revenue growth was evenly split between price and volume, and credited the company’s performance to the commercial success of new products such as Credelio Quattro and Zenrelia. Management described a rebound in U.S. retail trends and noted the resilience of its international pet health and farm animal segments, despite challenges like colder weather and a tough U.S. retail backdrop early in the quarter. CFO Todd Young added that disciplined manufacturing and operating cost management contributed to margin expansion, even as investments in product launches and R&D continued.

Looking ahead, Elanco’s management attributes its raised full-year revenue guidance to momentum from its innovation portfolio and a rebound in retail demand. CEO Jeff Simmons stated, “We expect accelerating quarter-on-quarter growth with Q2 up 4% to 6%,” pointing to the ramp-up of new product launches. The company plans significant investment in marketing and distribution, particularly for its Big 6 innovations, to capture opportunities during the peak parasiticide season. While Elanco expects further revenue gains from these launches and ongoing expansion in its farm animal business, management flagged potential headwinds from tariffs and macroeconomic volatility. CFO Todd Young said the company is maintaining a prudent approach, balancing currency tailwinds and innovation-driven growth with uncertainty in the external environment.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong uptake of new products, operational discipline, and a diversified portfolio that helped offset temporary challenges in U.S. retail channels.

• New products boost sales: The launch of Credelio Quattro and continued uptake of Zenrelia contributed significantly to growth, with Credelio Quattro quickly capturing a 10% share of broad-spectrum sales in U.S. veterinary clinics and Zenrelia reaching approximately 11,000 U.S. clinics, about 35% of the market.
• Innovation pipeline momentum: Elanco increased its full-year innovation revenue expectations, citing the strong performance of its Big 6 products. Management indicated that this basket of products, which includes breakthroughs in parasiticides and dermatology, is expected to drive company growth for the next decade.
• Farm animal business strength: Experior, a key product for cattle, maintained robust adoption following new regulatory clearances, while Bovaer showed continued demand in dairy markets despite delayed government incentives. These products are supporting both revenue growth and portfolio resilience.
• Operational and supply chain adaptations: Management highlighted proactive measures to mitigate tariff impacts, including inventory management, selective pricing, and strategic sourcing. These steps, combined with favorable foreign exchange, have offset much of the expected tariff-related headwind for 2025.
• Manufacturing and cost control: Margin expansion was supported by better-than-expected manufacturing performance, with management emphasizing ongoing focus on productivity, cost discipline, and targeted investments in facilities expansion and product launches.

Drivers of Future Performance

Elanco’s outlook is anchored by ongoing investments in product launches, a focus on innovation, and careful management of tariff and macroeconomic risks.

• Peak season investments: The company will substantially increase operating expenses in Q2 to support the launch and marketing of key products, especially during the Northern Hemisphere’s peak parasiticide season. Management anticipates that these investments will drive accelerating revenue in the second half of the year.
• Tariff and currency dynamics: While new U.S. and China tariffs present a risk, management believes most of the estimated impact for 2025 is balanced by foreign exchange benefits and intervention strategies such as supply chain optimization and value-based price increases.
• Innovation and portfolio expansion: Elanco’s growth outlook depends on the success of its Big 6 innovation launches, further label expansions (especially for Zenrelia), and geographic expansion, particularly in international pet health and farm animal markets. The company also expects new regulatory approvals and increased clinic penetration for these products.

Catalysts in Upcoming Quarters

In upcoming quarters, the StockStory team will be monitoring (1) the ramp-up and sustained demand for Credelio Quattro and Zenrelia, (2) execution and market share gains in the farm animal segment, especially with Experior and Bovaer, and (3) the company’s ability to navigate tariff headwinds without eroding margins. Progress on regulatory approvals and label expansions, as well as further deleveraging, will also be key markers of strategic execution.

Elanco currently trades at a forward P/E ratio of 17.8×. Should you double down or take your chips? The answer lies in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.